🏛️ Verified NIH Record • Updated 2025-11-18
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (NCT06140836)
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0221 — Des Moines, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (122 Sites)
Showing the first 25 of 122 sites.
- Local Institution - 0221 — Des Moines, Iowa
- Local Institution - 0075 — Boston, Massachusetts
- Local Institution - 0201 — Boston, Massachusetts
- Local Institution - 0210 — Mineola, New York
- Local Institution - 0134 — New York, New York
- Local Institution - 0214 — Tacoma, Washington
- Local Institution - 0092 — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Instituto Alexander Fleming — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Local Institution - 0091 — ABB, Buenos Aires F.D.
- Local Institution - 0106 — Buenos Aires,
- Local Institution - 0207 — Buenos Aires,
- Local Institution - 0093 — Córdoba,
- Local Institution - 0041 — Vienna,
- Local Institution - 0073 — Belo Horizonte, Minas Gerais
- Local Institution - 0033 — Porto Alegre, Rio Grande do Sul
- Local Institution - 0034 — Porto Alegre, Rio Grande do Sul
- Local Institution - 0029 — Barretos, São Paulo
- Local Institution - 0037 — São José do Rio Preto, São Paulo
- Local Institution - 0209 — São Paulo, São Paulo
- Local Institution - 0147 — São Paulo, São Paulo
- Local Institution - 0098 — Rio de Janeiro,
- Local Institution - 0108 — Rio de Janeiro,
- Local Institution - 0032 — São Paulo,
- Local Institution - 0114 — São Paulo,
- Local Institution - 0002 — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.